Building Resilience: CDMO Strategies for Drug Supply Chain Stability

In this article, AustinPx CEO Elizabeth Hickman highlights the critical role small-molecule CDMOs play in stabilizing today’s strained pharmaceutical supply chains. With more than 250 essential drugs in shortage, CDMOs must balance agility with scientific rigor to meet rising demand, regulatory pressures, and funding challenges. Hickman explores how high-science, high-touch strategies, scalable manufacturing, and patient-centric innovation such as IV-to-oral conversions and pill burden reduction can help CDMOs deliver resilient solutions and long-term value.